THERAPY DOSSIER · th-6a16a3f3eaab

Aloin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL497001 ↗
ChEMBL max phase: -1 / 4 (development scale, not regulatory approval)
Synonyms: Alloin; Aloin a; Aloins; Aloinum; Barbaloin
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32419528 ↗2020Reported benefit

Aloin suppresses lipopolysaccharide-induced acute lung injury by inhibiting NLRP3/NF-kappaB via activation of SIRT1 in mice.

MouseEndotoxin/LPSC57BL/6Female1 h before LPS administration (pretreatment)

Model: Lipopolysaccharide-induced acute lung injury

Aloin pretreatment reduced inflammatory cell influx, cytokines, oedema, myeloperoxidase activity and lipid peroxidation, restored GSH and SOD, and suppressed NF-kappaB and NLRP3 activation; protection was reversed by SIRT1 inhibition.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…